Kamada (NASDAQ:KMDA) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Kamada Ltd. (NASDAQ:KMDA)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $7.09 and traded as low as $6.89. Kamada shares last traded at $6.92, with a volume of 89,402 shares.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KMDA. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 15th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $13.00.

Kamada Stock Performance

The company has a market cap of $397.93 million, a P/E ratio of 20.35, a P/E/G ratio of 0.70 and a beta of 0.92. The stock has a 50-day moving average of $6.84 and a two-hundred day moving average of $7.09.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The firm had revenue of $47.01 million for the quarter, compared to the consensus estimate of $154.21 million. Kamada had a net margin of 11.22% and a return on equity of 7.41%. As a group, sell-side analysts forecast that Kamada Ltd. will post 0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of KMDA. NewEdge Advisors LLC boosted its stake in Kamada by 4.2% during the 3rd quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock valued at $366,000 after purchasing an additional 2,125 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Kamada by 201.0% in the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after purchasing an additional 41,111 shares during the last quarter. Man Group plc bought a new position in shares of Kamada during the third quarter valued at $199,000. Two Sigma Investments LP boosted its position in shares of Kamada by 4.3% during the third quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after buying an additional 4,504 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Kamada by 1.2% during the third quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock valued at $1,779,000 after buying an additional 2,943 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.